Image pharmaphorum Editor Market Access Is it time to rethink electronic prescribing in the US? It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime. Market Access Closing the digital expectation gap in pharma Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”. Market Access Combination pricing: access to the future of oncology treatm... Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world. Market Access Rethinking value: why diverse viewpoints matter Value is a tricky concept to capture accurately. Load more results
Market Access Is it time to rethink electronic prescribing in the US? It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime.
Market Access Closing the digital expectation gap in pharma Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”.
Market Access Combination pricing: access to the future of oncology treatm... Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world.
Market Access Rethinking value: why diverse viewpoints matter Value is a tricky concept to capture accurately.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
